Skip to main content

Opus Genetics, Inc.

IRD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001228627

In the last 90 days, Opus Genetics, Inc. insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $236.4M in total; no superinvestor holds it.

Holders of 5% or more of IRD

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Opus Genetics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of IRD
HolderLatest formStakeChangeFirst filedLatest filingFiling
Perceptive Advisors LLC13G9.99%4.51M sharesNewMar 31, 20251 filingMar 31, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

1 Schedule 13D or 13G filing on Opus Genetics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on IRD
Filed (ET)FilerFormStakeChangeEvent dateFiling
Mar 31, 20254:10 PM ETPerceptive Advisors LLCand 2 others13G9.99%4.51M sharesNewMar 24, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Opus Genetics, Inc. shares.

No Form 144 notices for Opus Genetics, Inc. are on file.